Matches in Wikidata for { <http://www.wikidata.org/entity/Q73341871> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q73341871 description "article scientifique publié en 1999" @default.
- Q73341871 description "artículu científicu espublizáu en xunetu de 1999" @default.
- Q73341871 description "im Juli 1999 veröffentlichter wissenschaftlicher Artikel" @default.
- Q73341871 description "scientific article published on 01 July 1999" @default.
- Q73341871 description "wetenschappelijk artikel" @default.
- Q73341871 description "наукова стаття, опублікована в липні 1999" @default.
- Q73341871 name "Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)" @default.
- Q73341871 name "Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)" @default.
- Q73341871 type Item @default.
- Q73341871 label "Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)" @default.
- Q73341871 label "Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)" @default.
- Q73341871 prefLabel "Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)" @default.
- Q73341871 prefLabel "Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)" @default.
- Q73341871 P1433 Q73341871-840A8992-D203-4DE9-A44A-8D47766258FE @default.
- Q73341871 P1476 Q73341871-C5400B8E-FEB1-47CE-9F23-3505AEA64416 @default.
- Q73341871 P2093 Q73341871-3D7428AE-D8C0-44AC-A1B8-9D66C0737195 @default.
- Q73341871 P2093 Q73341871-5A1F5C40-4C65-4C0B-AAA9-C3128B23C1E1 @default.
- Q73341871 P2093 Q73341871-7028E422-AEF2-43A1-8306-F8D926FB191F @default.
- Q73341871 P2093 Q73341871-988054A7-7C21-4CB5-9369-38786DA70635 @default.
- Q73341871 P2093 Q73341871-BFD65D0C-634D-482F-B9B5-EEE2CEED9724 @default.
- Q73341871 P2093 Q73341871-D8D46BC2-3B96-4FC4-A522-A5C7D0E624CE @default.
- Q73341871 P2093 Q73341871-DF51AD93-2022-44C6-8F0B-7E919DA3048E @default.
- Q73341871 P2093 Q73341871-EC030A6F-7D67-4538-8939-FA8BBFD93F1F @default.
- Q73341871 P304 Q73341871-6FC796C0-02D8-4B84-8C43-F54AF6993656 @default.
- Q73341871 P31 Q73341871-907F88A7-74AF-4FD2-96C1-44407FAFD34D @default.
- Q73341871 P407 Q73341871-3AF4DA3F-196A-4FAD-83CC-15EF3BE027E6 @default.
- Q73341871 P433 Q73341871-48385EB7-16FD-4F37-866B-267A217E7480 @default.
- Q73341871 P478 Q73341871-58F37218-4712-4062-AF05-2B728AA09D2D @default.
- Q73341871 P50 Q73341871-97846854-901C-464C-87C5-565BBADB1407 @default.
- Q73341871 P577 Q73341871-58CC7018-8A2A-48BF-9A55-086B91099B58 @default.
- Q73341871 P698 Q73341871-43A449E9-2515-42BF-8F36-F1A535C209A8 @default.
- Q73341871 P698 10629645 @default.
- Q73341871 P1433 Q326290 @default.
- Q73341871 P1476 "Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)" @default.
- Q73341871 P2093 "Berkarda B" @default.
- Q73341871 P2093 "Buyukunal E" @default.
- Q73341871 P2093 "Demir G" @default.
- Q73341871 P2093 "Demirelli F" @default.
- Q73341871 P2093 "Molinas-Mandel N" @default.
- Q73341871 P2093 "Ozguroglu M" @default.
- Q73341871 P2093 "Sayhan N" @default.
- Q73341871 P2093 "Serdengecti S" @default.
- Q73341871 P304 "3517-3520" @default.
- Q73341871 P31 Q13442814 @default.
- Q73341871 P407 Q1860 @default.
- Q73341871 P433 "4C" @default.
- Q73341871 P478 "19" @default.
- Q73341871 P50 Q57015385 @default.
- Q73341871 P577 "1999-07-01T00:00:00Z" @default.
- Q73341871 P698 "10629645" @default.